Trastuzumab Deruxtecan Shows Clinical Activity in HER2+ Solid Tumors
Funda Meric-Bernstam, MD, discusses the phase 2 DESTINY-PanTumor02 trial of fam-trastuzumab deruxtecan-nxki for the treatment of patients with HER2-expressing solid tumors.
Evaluating Trastuzumab Deruxtecan in the DESTINY-PanTumor02 Trial
Funda Meric-Bernstam, MD, discusses fam-trastuzumab deruxtecan-nxki and the evaluation of the agent in the phase 2 DESTINY-PanTumor02 trial.